Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.
The user, a 27-year-old male, has been treating early hair loss with topical finasteride and minoxidil, then switched to oral finasteride and dutasteride, but has seen no improvement and plans to add oral minoxidil. Despite treatment, hair loss has progressed from Norwood 1-1.5 to Norwood 3, with noticeable thinning, especially on the left side.
Switching from finasteride to dutasteride worsened hair loss and caused a burning sensation. Users suggest sticking with finasteride, using ketoconazole shampoo, and consulting a dermatologist.
Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
A 30-year-old man shares his successful hair loss protocol, which includes finasteride, Nizoral shampoo, low-level laser therapy, microneedling, and past use of oral minoxidil. He plans to consider dutasteride and possibly hair transplants in the future, while advising caution with crown transplants before age 35.
A user took finasteride for hair loss 10 years ago, stopped after a month, and has since suffered from severe erectile dysfunction (ED) and other symptoms. They shared blood test results seeking advice for their condition, and others discussed similar experiences with finasteride and related drugs.
User on Dut, oral minox 20 mg, Saw Palmetto, Pumpkin Oil, RU, 8% topical minox, and topical fina for hair loss; top of head improves, but retrograde alopecia worsens. Asks for options besides exosomes and where to find topical melatonin.
The conversation discusses using GHK Cu + AHK Cu peptides combined with topical dutasteride and minoxidil for hair regrowth. It mentions negative side effects of finasteride and promotes a specific copper peptide serum.
A 19-year-old seeks advice on obtaining a dutasteride prescription for hair loss, despite it being typically prescribed for urinary or prostate issues. Another user suggests starting with minoxidil or finasteride and exploring other telehealth options for dutasteride.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.
The struggles of hair loss at a young age and available treatments, such as medication (Finasteride, Minoxidil, Dutasteride, Derma Rolling) and potential options for hair systems or cloning in Japan. People discussed their own experiences with trying to cope with the emotional aspects of this condition.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
The user wants to donate plasma to save for a hair transplant but can't take finasteride or dutasteride due to plasma center restrictions. They are considering using minoxidil and biotin instead and are seeking advice on alternative treatments.
The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.
New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.
Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.
The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hair follicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Some people may not respond to topical minoxidil due to low SULT1A1 enzyme activity, but oral minoxidil can be effective. Tretinoin may enhance minoxidil's effectiveness, and some users prefer oral minoxidil despite side effects.
Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.